IL125950A0 - Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy - Google Patents
Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapyInfo
- Publication number
- IL125950A0 IL125950A0 IL12595098A IL12595098A IL125950A0 IL 125950 A0 IL125950 A0 IL 125950A0 IL 12595098 A IL12595098 A IL 12595098A IL 12595098 A IL12595098 A IL 12595098A IL 125950 A0 IL125950 A0 IL 125950A0
- Authority
- IL
- Israel
- Prior art keywords
- administering
- methods
- receptor antagonists
- dopamine agonist
- ampa receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5809897P | 1997-09-05 | 1997-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL125950A0 true IL125950A0 (en) | 1999-04-11 |
Family
ID=22014669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12595098A IL125950A0 (en) | 1997-09-05 | 1998-08-27 | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
Country Status (10)
Country | Link |
---|---|
US (1) | US6136812A (xx) |
EP (1) | EP0900568A3 (xx) |
JP (2) | JPH11158072A (xx) |
KR (1) | KR100440659B1 (xx) |
AU (1) | AU736254B2 (xx) |
CA (1) | CA2246839C (xx) |
HU (1) | HUP9802021A3 (xx) |
IL (1) | IL125950A0 (xx) |
NZ (1) | NZ331741A (xx) |
ZA (1) | ZA988139B (xx) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6627755B1 (en) * | 1997-06-09 | 2003-09-30 | Pfizer Inc | Quinazolin-4-one AMPA antagonists |
US7230000B1 (en) * | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US7671200B2 (en) | 1999-10-27 | 2010-03-02 | Cytokinetics, Inc. | Quinazolinone KSP inhibitors |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
EP1278748B1 (en) * | 2000-04-25 | 2011-03-23 | ICOS Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
GB0017952D0 (en) * | 2000-07-22 | 2000-09-13 | Univ Manchester | Treatment of dyskinesia |
AU2002331220B2 (en) * | 2001-09-12 | 2007-06-07 | Merck Patent Gmbh | Novel use of substituted aminomethyl chromans for the treatment of movement disorder and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders |
WO2003043961A2 (en) * | 2001-11-19 | 2003-05-30 | Iconix Pharmaceuticals, Inc. | Modulators of rho c activity |
WO2003043995A1 (en) | 2001-11-20 | 2003-05-30 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
ES2291543T3 (es) * | 2001-12-06 | 2008-03-01 | MERCK & CO., INC. | Inhibicion de kinesina mitotica. |
CA2475879A1 (en) | 2002-02-15 | 2003-08-28 | Cytokinetics, Inc. | Synthesis of quinazolinones |
JP2005530785A (ja) | 2002-05-09 | 2005-10-13 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、及び方法 |
PL373412A1 (en) | 2002-05-09 | 2005-08-22 | Cytokinetics, Inc. | Pyrimidinone compounds, compositions and methods of their use for treating cellular proliferative diseases |
US7038048B2 (en) | 2002-05-23 | 2006-05-02 | Cytokinetics, Inc. | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use |
US7041676B2 (en) * | 2002-06-14 | 2006-05-09 | Cytokinetics, Inc. | Compounds, compositions, and methods |
US7211580B2 (en) | 2002-07-23 | 2007-05-01 | Cytokinetics, Incorporated | Compounds, compositions, and methods |
CN1681512B (zh) * | 2002-09-13 | 2011-11-09 | 默塔克神经科学有限公司 | 2,3-苯并二氮杂草在制备治疗与基底神经节相关的运动疾病的药物中的应用 |
US7557115B2 (en) | 2002-09-30 | 2009-07-07 | Cytokinetics, Inc. | Compounds, compositions, and methods |
CN1894234A (zh) * | 2003-03-25 | 2007-01-10 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
WO2005041888A2 (en) * | 2003-11-03 | 2005-05-12 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions and methods |
US7439254B2 (en) * | 2003-12-08 | 2008-10-21 | Cytokinetics, Inc. | Compounds, compositions, and methods |
EP1761540B1 (en) | 2004-05-13 | 2016-09-28 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
JPWO2006109876A1 (ja) * | 2005-04-08 | 2008-11-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 不随意運動治療剤 |
US20090298856A1 (en) * | 2005-05-11 | 2009-12-03 | Rebecca Elizabeth Brown | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) |
SI1942898T2 (sl) | 2005-09-14 | 2014-08-29 | Takeda Pharmaceutical Company Limited | Dipeptidil-peptidazni inhibitorji za zdravljenje diabetesa |
CN102675221A (zh) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
WO2007056124A2 (en) * | 2005-11-04 | 2007-05-18 | Hydra Biosciences, Inc. | Compounds for modulating trpv3 function |
US8003656B2 (en) * | 2006-08-23 | 2011-08-23 | Neurogen Corporation | 2-phenoxy pyrimidinone analogues |
AU2007288198A1 (en) * | 2006-08-23 | 2008-02-28 | Neurogen Corporation | Haloalkyl-substituted pyrimidinone derivatives |
MX2009003673A (es) | 2006-10-04 | 2009-04-22 | Pfizer Prod Inc | Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio. |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
WO2008140750A1 (en) * | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
CA3092449A1 (en) | 2008-11-13 | 2010-05-20 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
WO2010088408A2 (en) * | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor antagonists for the treatment of neurological conditions |
MX2011009955A (es) | 2009-03-24 | 2011-11-18 | Gilead Calistoga Llc | Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso. |
CN102458410A (zh) | 2009-04-20 | 2012-05-16 | 吉联亚·卡利斯托加有限责任公司 | 治疗实体瘤的方法 |
MX2012000817A (es) | 2009-07-21 | 2012-05-08 | Gilead Calistoga Llc | Tratamiento para desordenes del higado con inhibidores pi3k. |
AU2013203620B2 (en) | 2012-03-05 | 2015-11-19 | Gilead Calistoga Llc | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
PL3083630T3 (pl) | 2013-12-20 | 2020-02-28 | Gilead Calistoga Llc | Sposoby otrzymywania inhibitorów 3-kinazy fosfatydyloinozytolu |
JP2017500319A (ja) | 2013-12-20 | 2017-01-05 | ギリアード カリストガ エルエルシー | (s)−2−(1−(9h−プリン−6−イルアミノ)プロピル)−5−フルオロ−3−フェニルキナゾリン−4(3h)−オンの塩酸塩の多形形態 |
NZ726360A (en) | 2014-06-13 | 2018-04-27 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
WO2017003723A1 (en) | 2015-07-01 | 2017-01-05 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
EP3394056B1 (en) | 2015-12-22 | 2021-04-14 | Shy Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
MX2019014875A (es) | 2017-06-21 | 2021-01-29 | SHY Therapeutics LLC | Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica. |
WO2019023278A1 (en) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | MODULATORS OF SOMATOSTATIN AND USES THEREOF |
AU2021212754A1 (en) | 2020-01-29 | 2022-08-04 | Kamari Pharma Ltd. | Compounds and compositions for use in treating skin disorders |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4183931A (en) * | 1977-09-08 | 1980-01-15 | Research Corporation | 2-Ketoalkyl-4(3H)-quinazolinones |
US5395827A (en) * | 1986-04-09 | 1995-03-07 | Guilford Pharmaceuticals Inc. | ω-[2-(phosphonoalkyl)phenyl]-2-aminoalkanoic acids as antagonists of excitatory amino acid receptors |
US5268378A (en) * | 1990-05-31 | 1993-12-07 | Merck Sharp & Dohme, Limited | Dioxo-tetrahydroquinoline derivatives |
GB9022785D0 (en) * | 1990-10-19 | 1990-12-05 | Merck Sharp & Dohme | Therapeutic agents |
GB9026389D0 (en) * | 1990-12-05 | 1991-01-23 | Merck Sharp & Dohme | Therapeutic agents |
US5639751A (en) * | 1990-12-21 | 1997-06-17 | Cyogyszerkutato Intezet Kft | N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic neurodegenerative disorders |
US5521174A (en) * | 1990-12-21 | 1996-05-28 | Gyogyszerkutato Intezet Kv. | N-acyl-2,3-benzodiazepine derivatives and a method of treating spasms of the skeletal musculature therewith |
US5519019A (en) * | 1990-12-21 | 1996-05-21 | Gyogyszerkutato Intezet | N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions containing them and process for preparing same |
WO1992013535A1 (en) * | 1991-02-06 | 1992-08-20 | Research Corporation Technologies, Inc. | Anticonvulsant substituted quinazolones |
ATE162075T1 (de) * | 1991-09-09 | 1998-01-15 | Warner Lambert Co | Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält |
DK162491D0 (da) * | 1991-09-20 | 1991-09-20 | Novo Nordisk As | Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne |
PT101004B (pt) * | 1991-10-26 | 1999-10-29 | Schering Ag | Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem |
GB9125485D0 (en) * | 1991-11-29 | 1992-01-29 | Merck Sharp & Dohme | Therapeutic agents |
GB9125515D0 (en) * | 1991-11-29 | 1992-01-29 | Merck Sharp & Dohme | Therapeutic agents |
GB9200781D0 (en) * | 1992-01-15 | 1992-03-11 | Merck Sharp & Dohme | Therapeutic agents |
GB9206266D0 (en) * | 1992-03-23 | 1992-05-06 | Merck Sharp & Dohme | Therapeutic agents |
GB9210393D0 (en) * | 1992-05-15 | 1992-07-01 | Merck Sharp & Dohme | Therapeutic agents |
ATE404201T1 (de) * | 1992-06-22 | 2008-08-15 | Univ California | Glycinrezeptorantagonisten und ihre verwendung |
US5284957A (en) * | 1992-09-03 | 1994-02-08 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
US5356902A (en) * | 1992-11-06 | 1994-10-18 | Eli Lilly And Company | Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists |
US5364876A (en) * | 1992-12-02 | 1994-11-15 | Guilford Pharmaceuticals Inc. | Omega-[2-(alkyl)phenyl]-2-aminoalkanoic acids as antagonists of excitatory amino acid receptors |
US5342946A (en) * | 1992-12-02 | 1994-08-30 | Guilford Pharmaceuticals Inc. | Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors |
DK31093D0 (xx) * | 1993-03-19 | 1993-03-19 | Novo Nordisk As | |
WO1994026746A1 (en) * | 1993-05-06 | 1994-11-24 | Novo Nordisk A/S | [1,2,4]TRIAZOLO[4,3-a]QUINOXALINE COMPOUNDS, THEIR PREPARATION AND USE |
US5631373A (en) * | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
ATE214069T1 (de) * | 1994-02-11 | 2002-03-15 | Novo Nordisk As | Heterocyclische verbindungen und ihre herstellung und verwendung |
US5580877A (en) * | 1994-04-25 | 1996-12-03 | Merck Sharp & Dohme Ltd. | Pyrazolo-quinoline derivatives for treating cerebral ischemia |
US5446051A (en) * | 1994-05-31 | 1995-08-29 | Eli Lilly And Company | Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists |
CA2200056A1 (en) * | 1994-09-16 | 1996-03-21 | Novo Nordisk A/S | [1,2,4]triazolo[4,3-a]quinoxalinone derivatives, their preparation and use |
US5654303A (en) * | 1995-06-07 | 1997-08-05 | Warner-Lambert Company | Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
US5614508A (en) * | 1995-06-07 | 1997-03-25 | Warner-Lambert Company | Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists |
PT901487E (pt) * | 1996-05-15 | 2003-08-29 | Pfizer | 4(3h)-quinazolinonas 2,3,6-trissubstituidas |
-
1998
- 1998-08-27 IL IL12595098A patent/IL125950A0/xx unknown
- 1998-08-31 JP JP10245269A patent/JPH11158072A/ja active Pending
- 1998-09-04 NZ NZ331741A patent/NZ331741A/xx unknown
- 1998-09-04 AU AU83120/98A patent/AU736254B2/en not_active Ceased
- 1998-09-04 HU HU9802021A patent/HUP9802021A3/hu unknown
- 1998-09-04 US US09/148,974 patent/US6136812A/en not_active Expired - Fee Related
- 1998-09-04 EP EP98307181A patent/EP0900568A3/en not_active Withdrawn
- 1998-09-05 KR KR10-1998-0036653A patent/KR100440659B1/ko not_active IP Right Cessation
- 1998-09-07 ZA ZA9808139A patent/ZA988139B/xx unknown
- 1998-09-08 CA CA002246839A patent/CA2246839C/en not_active Expired - Fee Related
-
2001
- 2001-05-02 JP JP2001134816A patent/JP2001316267A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0900568A2 (en) | 1999-03-10 |
ZA988139B (en) | 2000-03-22 |
HUP9802021A3 (en) | 2001-05-28 |
KR19990029570A (ko) | 1999-04-26 |
EP0900568A3 (en) | 2001-05-02 |
HUP9802021A2 (hu) | 1999-05-28 |
US6136812A (en) | 2000-10-24 |
JPH11158072A (ja) | 1999-06-15 |
NZ331741A (en) | 2000-08-25 |
AU736254B2 (en) | 2001-07-26 |
JP2001316267A (ja) | 2001-11-13 |
HU9802021D0 (en) | 1998-10-28 |
CA2246839C (en) | 2002-11-12 |
CA2246839A1 (en) | 1999-03-05 |
AU8312098A (en) | 1999-03-18 |
KR100440659B1 (ko) | 2004-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU9802021D0 (en) | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | |
AU2666901A (en) | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | |
EP1027011A4 (en) | ADMINISTRATION OF 5-HT RECEPTOR AGONISTS AND ANTAGONISTS INCLUDING ACTIVE SUBSTANCES FOR THE TREATMENT OF EARLY SEED EATING | |
IL114116A0 (en) | Delivery of therapeutic agents to receptors using polysaccharides | |
WO2004058717A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
IL142921A0 (en) | USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS | |
WO2001005763A3 (en) | Compounds with activity on muscarinic receptors | |
AU2002300464A1 (en) | Apoliprotein A-I Agonist And Their Use To Treat Dyslipidemic Disorders | |
WO2000064441A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
SG188700A1 (en) | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors | |
IL147977A0 (en) | Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain | |
PL341114A1 (en) | Antagonists of thrombosin receptors | |
IL125953A0 (en) | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | |
SG83723A1 (en) | Novel therapeutic agents that modulate 5ht receptors | |
IL143385A0 (en) | 5ht1 antagonists for antidepressant therapy | |
HUP0102436A3 (en) | Use of reboxetin for preparation of medicament for nervous disorders | |
AU7788500A (en) | Use of substance p antagonists for influencing the circadian timing system | |
HUP0201405A2 (en) | Pharmaceutical composition for therapeutic use of melatonin | |
AU2002300534A1 (en) | Methods of Administering an AMPA Receptor Antagonist to Treat Dyskinesias Associated with Dopamine Agonist Therapy | |
WO2000076500A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
AU2193797A (en) | Delivery of therapeutic agents to the prostate | |
WO2001046198A3 (en) | Nonpeptide kappa opioid receptor antagonists | |
ZA98484B (en) | Use of beta3-adrenergic receptor agonists for the preparation of healing drugs | |
AU8553898A (en) | Use of 2,3-benzodiazepine derivatives for the preparation of pharmaceutical compositions to treat diseases connected with the endogenous opioid system | |
EP1508337A3 (en) | Uses for eph receptor antagonists and agonists to treat vascular disorders |